Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael Andrew Postow, Robert Sidlow, Matthew David Hellmann · New England Journal of Medicine · 2018
The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients with cancer. This review surveys the adverse effects and their management.
Cited by 4,807 works. doi:10.1056/nejmra1703481
Authors
References
- The National Comprehensive Cancer Network
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab